25 Aug 2023

Real-world data platform Atropos Health moves into life sciences

Atropos Health, a platform grounded in real-world data, has unveiled the establishment of a life science advisory board and a strategic entry into the life sciences arena. Within this new domain, Atropos Health presents an array of AI-driven innovations, encompassing data assessment, evidence formulation, and amplified analytical capabilities.


At the core of Atropos Health's offerings is its application, which empowers medical practitioners with access to tangible real-world evidence to inform their clinical judgments and research pursuits.


Hailing from California, the company extends its capabilities through the introduction of the Green Button, a resource tailored for clinical informatics services. This feature empowers users to receive publication-quality reports from observational studies in as little as 48 hours, all aligned with the inquiries posed by the user's clinical context.


Notably, Atropos Health has unveiled a specialised iteration of the Green Button tailored specifically for life sciences stakeholders. This specialised version facilitates the comprehensive utilisation of real-world datasets for an array of purposes, including cohort analysis, protocol viability assessment, hypothesis validation, treatment pathway elucidation, label expansion initiatives, regulatory endeavours, patient journey comprehension, and identification of unmet medical requirements. Providers can harness data from their internal platforms or opt to leverage Atropos Health's extensive network.


Dr. Brigham Hyde, CEO and Co-founder of Atropos Health, emphasised, "The production of evidence is the lifeline of the life sciences industry. Through the Atropos Evidence Platform, researchers can significantly amplify and expedite their capacity to generate evidence – all while optimising the efficiency of their existing workforce and minimising the need for outsourced personnel. Furthermore, the Atropos Evidence Network empowers researchers to swiftly derive evidence from diverse data sources without being encumbered by extensive onboarding procedures or infrastructure impediments."


Click here to read the original news story.